Govt Urged To Impose 15% Duty on Cotton Yarn Export
Knitwear exporters from Tirupur have requested the Centre to impose 15% export duty on cotton yarn to prevent a spurt in yarn prices in the domestic market. This would help the knitwear sector have a level playing field in international markets and compete effectively, Tirupur Exporters' Association president A Shaktivel said in a representation to commerce minister Anand Sharma.
No Ban, Only Stricter Checks on Food Imports From Japan
India will not ban food imports from Japan immediately as no item has yet tested positive for radioactive contamination. All food imports, however, will now need mandatory ‘no-radiation’ certification
Ranbaxy Gets Relief in Lipitor Case
The US drug regulator has opposed American firm Mylan’s request to strip Ranbaxy Laboratories of its six months exclusive right to sell a low-priced version of the world’s best-selling drug Lipitor in the US. The US Food and Drug Authority (FDA) has inprinciple allowed Ranbaxy to sell a generic version of the medicine from end of 2011, after original drugmaker Pfizer’s patent expires in November.
The six months headway can bring in as much as $500-600 million in revenues for India’s largest drugmaker.
Knitwear exporters from Tirupur have requested the Centre to impose 15% export duty on cotton yarn to prevent a spurt in yarn prices in the domestic market. This would help the knitwear sector have a level playing field in international markets and compete effectively, Tirupur Exporters' Association president A Shaktivel said in a representation to commerce minister Anand Sharma.
No Ban, Only Stricter Checks on Food Imports From Japan
India will not ban food imports from Japan immediately as no item has yet tested positive for radioactive contamination. All food imports, however, will now need mandatory ‘no-radiation’ certification
Ranbaxy Gets Relief in Lipitor Case
The US drug regulator has opposed American firm Mylan’s request to strip Ranbaxy Laboratories of its six months exclusive right to sell a low-priced version of the world’s best-selling drug Lipitor in the US. The US Food and Drug Authority (FDA) has inprinciple allowed Ranbaxy to sell a generic version of the medicine from end of 2011, after original drugmaker Pfizer’s patent expires in November.
The six months headway can bring in as much as $500-600 million in revenues for India’s largest drugmaker.
No comments:
Post a Comment